SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
98
|
CROI Program Committee Chair Welcome to Tuesday
Nicolas Chomont
Université de Montréal, Montreal, Canada
GLP-1 Receptor Agonists: Are They a Cure for Everything? (ABSTRACT
24)
Todd T. Brown
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control (ABSTRACT
25)
Jeanne Marrazzo
Infectious Diseases Society of America, Arlington, VA, USA
A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART (ABSTRACT
133)
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B (ABSTRACT
134)
Julia Edgar
University of Oxford, Oxford, UK
Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control (ABSTRACT
135)
Katie Fisher
Aarhus University, Aarhus, Denmark
Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART (ABSTRACT
136)
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
Questions and Answers (Part 1)
CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption (ABSTRACT
137)
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones (ABSTRACT
138)
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo (ABSTRACT
139)
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT (ABSTRACT
140)
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
Questions and Answers (Part 2)
DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV (ABSTRACT
150)
Nicole Salazar-Austin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Empiric Valganciclovir Reduces Mortality in Infants Living With HIV and Severe Pneumonia (ABSTRACT
151)
Pablo Rojo
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies (ABSTRACT
152)
Gbolahan Ajibola
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
Very Early ART Initiation Associated With Sustained Aviremia in Time-to-Rebound Pediatric ATI (ABSTRACT
153)
Gabriela Z. L. Cromhout
University of KwaZulu-Natal, Durban, South Africa
Questions and Answers (Part 1)
DTG/3TC Is Noninferior to DTG-Based 3-Drug ART in Children With HIV: D3/Penta 21 Week-96 Results (ABSTRACT
154)
Anna Turkova
MRC Clinical Trials Unit at UCL, London, UK
Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End-of-Study Results (ABSTRACT
155)
Aditya Gaur
St Jude Children's Research Hospital, Memphis, TN, USA
Improved Viral Suppression and Retention: Randomized Trial of an Adolescent Transition Intervention (ABSTRACT
156)
Brian Zanoni
Emory University, Atlanta, GA, USA
Immunogenicity of 2- Versus 3-Dose HPV Vaccination by HIV Infection Status in Eswatini (ABSTRACT
157)
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
Questions and Answers (Part 2)
Efficacy and Safety of BLV 2 or 10 mg in CHD Including Patients With HIV/HBV: MYR301 Final Results (ABSTRACT
141)
David Wyles
Denver Health Medical Center, Denver, CO, USA
Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy (ABSTRACT
142)
Grace Haser
University of California San Francisco, San Francisco, CA, USA
Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study (ABSTRACT
143)
José M. Miró
Hospital Clinic of Barcelona, Barcelona, Spain
Early Detection of HCC via Active Surveillance in Persons With HIV in Uganda at High Risk (ABSTRACT
144)
Katuku Jim Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Questions and Answers (Part 1)
One-Month Versus 3-Month Rifapentine-Based Tuberculosis Preventive Therapy in People With HIV (ABSTRACT
145)
Anchalee Avihingsanon
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis (ABSTRACT
146)
Sean Wasserman
St George's University of London, London, UK
DOLPHIN-Moms: Pharmacokinetics and HIV Suppression With Once-Daily Dolutegravir and 3HP in Pregnancy (ABSTRACT
147)
Jyoti S. Mathad
Weill Cornell Medicine, New York, NY, USA
Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial (ABSTRACT
148)
Jayajothi Moodley
The Aurum Institute, Johannesburg, South Africa
Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment (ABSTRACT
149)
Constance A. Benson
University of California San Diego, La Jolla, CA, USA
Questions and Answers (Part 2)
Cluster-Randomized Stepped-Wedge Trial of HIV Rapid Testing and Risk Assessment in Primary Care (ABSTRACT
158)
Maria Jesus Perez Elias
Ramon y Cajal Hospital, Madrid, Spain
Enhanced Opt-Out HIV Screening & Linkage to Care for 216K Patients at 13 Community Health Centers (ABSTRACT
159)
Timothy Long MD
Health Choice Network, Miami, FL, USA
Electronic Health Record-Driven Universal HIV Screening and Missed Opportunities in Southeastern US (ABSTRACT
160)
David E. Hudon
Prisma Health, Greenville, SC, USA
Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya (ABSTRACT
161)
Peter Kyalo
Center for International Health, Education and Biosecurity (CIHEB) Kenya, Nairobi, Kenya
Questions and Answers (Part 1)
Global Analysis of HIV Oral PrEP-to-Need Ratios (PnR) in 2025 (ABSTRACT
162)
Andrew Hill
University of Liverpool, Liverpool, UK
The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda (ABSTRACT
163)
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
Urine Tenofovir and POC Viral Load Testing After ART Start: Week 72 Outcomes of STREAM-HIV Trial (ABSTRACT
164)
Paul K. Drain
University of Washington, Seattle, WA, USA
Evaluating the Viability of Self-Collected Blood for Remotely Testing HIV Suppression Among MSM (ABSTRACT
165)
Jeffrey Johnson
Centers for Disease Control and Prevention, Atlanta, GA, USA
Questions and Answers (Part 2)
Session Overview
Mark Sulkowski
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Simple Adiposity Measures Identify MASLD in People With HIV: Results From a US Multicenter Cohort (ABSTRACT
599)
Kara Wegermann
Duke University School of Medicine, Durham, NC, USA
Performance of Prediction Scores for Steatotic Liver Disease in Thai PWH on InSTI-Based ART (ABSTRACT
600)
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
Effect of DTG/3TC vs BIC/FTC/TAF on Steatotic Liver Disease: 96-Week Analysis of PASO-DOBLE Trial (ABSTRACT
598)
Juan Macias
University of Sevilla, Sevilla, Spain
Longitudinal Associations of Semaglutide With Liver Fibrosis Score in People With HIV (ABSTRACT
601)
Jimmy Ma
University of Washington, Seattle, WA, USA
Discussion With Audience Questions and Answers
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
98
|
